Crossmark

A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout

Crossref DOI link: https://doi.org/10.1007/s10157-020-01851-6

Published Online: 2020-01-22

Published Print: 2020-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hosoya, Tatsuo

Furuno, Kazuki

Kanda, Shingo
License Information

Text and Data Mining valid from 2020-01-22

Version of Record valid from 2020-01-22
More Information

Article History

Received: 17 September 2019

Accepted: 5 January 2020

First Online: 22 January 2020

Compliance with ethical standards

:

: TH was an advisor to Fuji Yakuhin Co., Ltd. regarding this study and received consultant and manuscript fees. KF and SK are employees of Mochida Pharmaceutical Co. Ltd.

: This study was conducted according to the Declaration of Helsinki, International Committee on Harmonization Good Clinical Practice guideline, and applicable local laws and regulations. The protocol was approved by the regulatory authorities in Japan and by the ethics committees of study centre. All patients provided written informed consent before starting any procedure in this study. The information of this study was registered with Clinical Trials.gov (ClinicalTrials.gov number: NCT03372200).

Document is current

Any future updates will be listed below